Protective effects of atractylenolide III on oxygen‐glucose‐deprivation/reperfusion‐induced injury in HT22 cells
Human & Experimental Toxicology · 2024
DOI: 10.1177/09603271241288508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human & Experimental Toxicology, 2024. Verfasst von Roujia Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao, Henan Province, Zhengzhou, China. Hauptthemen laut MEDLINE: Lactones, Sesquiterpenes, Reperfusion Injury, Glucose. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Research and Development Project of Henan Province.
Abstract (Originalsprache)
Background
Atractylenolide III (ATL III) is a natural bioactive compound, that possesses anti-inflammatory, antioxidant, and neuroprotective properties. However, whether ATL III can protect against neuronal injury induced by cerebral ischemia/reperfusion (I/R) have not yet been studied. This study aimed to investigate the protective effects of ATL III on neuronal injury using an oxygen-glucose deprivation/reperfusion (OGD/R) model in HT22 cells.
Methods
Establishment of OGD/R model to induce HT22 cell injury in vitro. Cell viability, live-dead cell staining, oxidative stress levels, and pro-inflammatory cytokine levels were detected using kits. Cell apoptosis was observed by flow cytometry, and the expression of Bax, Bcl-2, and Caspase-3 proteins was detected by western blot.
Results
ATL III significantly alleviates OGD/R-induced cell injury, as evidenced by the increased cell viability and reduced apoptosis rate. ATL III increased the levels of superoxide dismutase (SOD) and glutathione (GSH), while reducing malondialdehyde (MDA), reactive oxygen species (ROS), and the levels of TNF-α, IL-1β, and IL-6. The protein expression of Bax and Caspase-3 was downregulated, while Bcl-2 expression was upregulated by ATL III.
Conclusion
ATL III as a potential therapeutic agent for reducing neuronal injury by mitigating oxidative stress, apoptosis, and inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao, Henan Province, Zhengzhou, China.
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, China.
ORCID-Profile: Yucheng Li
Förderung
- National Natural Science Foundation of China
- Science and Technology Research and Development Project of Henan Province
Zitieren
APA
Guo, R., Quan, S., Liu, Y., Wang, J., Huang, Z., Guo, X., Bai, M., Xu, E., Yan, X., & Li, Y. (2024). Protective effects of atractylenolide III on oxygen‐glucose‐deprivation/reperfusion‐induced injury in HT22 cells. Human & Experimental Toxicology. https://doi.org/10.1177/09603271241288508
Vancouver
Guo R, Quan S, Liu Y, Wang J, Huang Z, Guo X, et al. Protective effects of atractylenolide III on oxygen‐glucose‐deprivation/reperfusion‐induced injury in HT22 cells. Human & Experimental Toxicology. 2024. doi:10.1177/09603271241288508
BibTeX
@article{Guo2024,
author = {Guo, Roujia and Quan, Siqi and Liu, Yuan and Wang, Jiahui and Huang, Ziyang and Guo, Xiuhui and Bai, Ming and Xu, Erping and Yan, Xiangli and Li, Yucheng},
title = {Protective effects of atractylenolide III on oxygen‐glucose‐deprivation/reperfusion‐induced injury in HT22 cells},
journal = {Human & Experimental Toxicology},
year = {2024},
doi = {10.1177/09603271241288508}
}
EUVIMED